Day: September 5, 2022

Alvotech Reports Update on  Initial AVT02 Biologics License Application

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication from the U.S. Food and Drug Administration (FDA) detailing its assessment of the March 2022 inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland and Alvotech’s subsequent written responses to the FDA.  The FDA’s Complete Response Letter to the initial biosimilar Biologics License Application (BLA) for AVT02 noted certain deficiencies related to the Reykjavik facility and stated that satisfactory resolution of the deficiencies is required before FDA may approve this BLA.  “Alvotech looks forward to addressing the deficiencies outlined in the post-application action letter and continuing to work with the FDA to close out the...

Continue reading

Automotive Wheel Rims Market Size Worth USD 33.33 Billion, Globally, by 2027 at 8.2% CAGR

Automotive Wheel Rims Market Size Worth USD 33.33 Billion, Globally, by 2027 at 8.2% CAGR

The automotive wheel rims market size is expected to grow from USD 19.18 Billion in 2019 to USD 33.33 Billion by 2027; it is estimated to grow at a CAGR of 8.2% from 2021 to 2027. Pune, India, Sept. 05, 2022 (GLOBE NEWSWIRE) — The global automotive wheel rims market size is expected to reach USD 33.33 billion by 2027, exhibiting a CAGR of 8.2% during the forecast period. The increasing sales of passenger cars will contribute positively to the growth of the market, states Fortune Business Insights, in a report, titled “Automotive Wheel Rims Market Size, Share & Industry Analysis, By Material Type (Alloy, Steel, Carbon Fiber), By Sales Channel Type (Original Equipment Manufacturer (OEM) and Aftermarket), By Vehicle Type (Passenger Cars and Commercial Vehicles), and Regional Forecast, 2020-2027.” The market size stood at USD...

Continue reading

Proactive news headlines including Great Boulder Resources, Aurumin Ltd, Silver Mines and New Century Resources

Proactive news headlines including Great Boulder Resources, Aurumin Ltd, Silver Mines and New Century Resources

Sydney, Sept. 05, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Great Boulder Resources Ltd (ASX:GBR) is riding high after it unveiled 15 metres at 35.82 g/t gold during reverse circulation (RC) drilling at the Side Well Gold Project’s Mulga Bill deposit in WA. Click here Aurumin Ltd (ASX:AUN) has unearthed a 352.8-metre gold hit, weighing in at 1.5 g/t, during diamond drilling at its wholly-owned Central Sandstone Gold Project in WA. Click here Silver Mines Ltd (ASX:SVL) has fielded a maiden mineral resource of 42.9 million ounces of silver equivalent for Bowdens Underground Zone of the Bowdens Silver Project in New South Wales, bringing the total project resource to 315 million silver equivalent ounces. Click here New...

Continue reading

Subsidiary of Hepsor AS acquires a property in Riga for development of 40-apartment residential building

Subsidiary of Hepsor AS acquires a property in Riga for development of 40-apartment residential building

Hepsor JG SIA, a subsidiary of Hepsor AS, signed a sale-purchase agreement on 1 September 2022, for acquiring a property in Jurmala Gatve Street, Imanta district, Riga. The property will accommodate a three-storey A-energy class residential building with 40 apartments and sellable area of approximately 2,500 m2. According to Henri Laks, member of the Management Board of Hepsor AS, the location of the property in the immediate vicinity of the Anninmuiža park, and the A-energy class of the planned building support the Group’s concept of green thinking. Construction of the new development project is expected to start at the end of 2023. Additional information: Hepsor has four residential development projects in Latvia in various stages. All 18 apartments in the Baložu 9 development project, completed this year, have been handed over...

Continue reading

<div>Enedo Oyj's Board of Directors' Statement on Inission AB's Mandatory Public Tender Offer for Enedo Oyj's Shares</div>

Enedo Oyj’s Board of Directors’ Statement on Inission AB’s Mandatory Public Tender Offer for Enedo Oyj’s Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL Enedo Oyj’s Board of Directors’ Statement on Inission AB’s Mandatory Public Tender Offer for Enedo Oyj’s Shares Inission AB (“Inission” or the “Offeror”) and Enedo Oyj (“Enedo” or the “Company”) have announced in stock exchange releases dated on August 1, 2022 that Inission will make a mandatory purchase offer for all of Enedo’s issued and outstanding shares (“Tender Offer”). The board of directors of Enedo has on September 5, 2022 decided to issue the following statement on the Tender Offer as required...

Continue reading

AS PRFOODS NOTICE OF NOTEHOLDERS’ MEETING

AS PRFOODS NOTICE OF NOTEHOLDERS’ MEETING

AS PRFOODS NOTICE OF NOTEHOLDERS’ MEETING AS PRFoods (registry code 11560713, registered address at Pärnu mnt 141, 11314 Tallinn, Estonia; “PRFoods”) hereby notifies persons holding the notes (the “Noteholders”) of the Issuer, due on 22 January 2025 and bearing ISIN code EE3300001577 (the “Notes”), issued under the Terms and Conditions of Secured Note Issue of AS PRFoods dated 14 January 2020 (which have been amended on 25 February 2020 and 25 February 2022) (the “Terms”), of convening a meeting of Noteholders (the “Meeting”). The Meeting will be held on 20.09.2022 at 9:00 (EET) at the offices of Advokaadibüroo COBALT OÜ, address Estonia pst 19 / Tatari tn 1, 10116 Tallinn (Kawe City). Registration for the Meeting will be open at the venue of the Meeting from 8:00 to 8:45 (EET). BACKGROUND PRFoods hereby convenes the Noteholders’...

Continue reading

Shell Plc Second Quarter 2022 Euro and GBP Equivalent Dividend Payments

Shell Plc Second Quarter 2022 Euro and GBP Equivalent Dividend Payments

September 5, 2022   The Board of Shell plc (“Shell”) today announced the pounds sterling and euro equivalent dividend payments in respect of the second quarter 2022 interim dividend, which was announced on July 28, 2022 at US$0.25 per ordinary share.   Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by August 26, 2022 will be entitled to a dividend of US$0.25, €0.2499 or 21.57p per ordinary share, respectively.   Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent any valid election to the contrary, shareholders (both holding...

Continue reading

Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

 Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma Results from the longest global Phase 3 open-label extension trial in this age group in asthma show sustained improvement in lung function, low rate of asthma attacks and a consistent safety profile for up to two years Data reinforce well-established efficacy and safety profile of Dupixent across age groups Paris and Tarrytown, N.Y. September 5, 2022. Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of...

Continue reading

Tallinna Sadam Investor Day “In the winds of the future” 14.09.2022

Tallinna Sadam Investor Day “In the winds of the future” 14.09.2022

Tallinna Sadam invites its current and future shareholders and other interested parties to the Investor Day “In the winds of the future”, which will take place on September 14 at 16.00 Estonian time in the cruise terminal at the Tallinn Old City Harbour. This time we will focus primarily on growth opportunities related to energy and offshore wind farms. Valdo Kalm and Andrus Ait, members of the management board of Tallinna Sadam, will introduce the company, give an overview of the financial results and future plans. Chief commercial officer Margus Vihman talks in more detail about new business projects and growth opportunities of Tallinna Sadam in the field of energy, and Ülo Eero, manager of the subsidiary TS Shipping, introduces the business opportunities of construction and maintenance of offshore wind farms from the perspective of...

Continue reading

Orion recalls Devisol Salmiakki dietary supplement from consumers

Orion recalls Devisol Salmiakki dietary supplement from consumers

Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_230tabl Devisol_Salmiakki_20mikrog_230tabl ORION CORPORATION                PRESS RELEASE                 5 SEPTEMBER 2022 AT 8.00 EEST         Orion recalls Devisol Salmiakki dietary supplement from consumers Orion is recalling all Devisol Salmiakki dietary supplement packages from consumers due to excessive levels of matrine in the product. Devisol Salmiakki has been on sale in Finland only starting from December 2021. Consumers are requested to return both opened and unopened Devisol Salmiakki products to the nearest pharmacy at the latest on 13 October 2022. The products will be reimbursed for the consumers. Empty packages or free samples will not be reimbursed. The recall does not concern Orion’s other Devisol products. The recall...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.